Methamphetamine and neuroHIV suppress astrocytic potassium channel function in the medial prefrontal cortex via

Lihua Chen1, Stefanie L Cassoday1, Joao I Mamede1

  • 1Department of Microbial Pathogens and Immunity, RUSH University Medical Center, Chicago, IL, United States.

Frontiers in Pharmacology
|December 10, 2025
PubMed
Abstract

Insights

Methamphetamine and neuroHIV impair astrocyte function by suppressing K+ channels. Combined use exacerbates astrocyte dysfunction, potentially worsening neuronal problems in MUD and neuroHIV.

Area of Science:

  • Neuroscience
  • Cellular Biology
  • Pharmacology

Background:

  • Methamphetamine use disorders (MUD) disrupt medial prefrontal cortex (mPFC) neuronal function.
  • HIV-associated neurocognitive disorders (neuroHIV) often co-occur with MUD, further complicating neurological health.
  • Both MUD and neuroHIV negatively impact astrocytes, critical cells supporting neuronal function, but the mechanisms remain unclear.

Purpose of the Study:

  • To investigate the impact of MUD and neuroHIV on astrocyte function, specifically focusing on K+ channel activity.
  • To elucidate the underlying mechanisms of astrocyte dysfunction in the context of combined MUD and neuroHIV.

Main Methods:

  • Utilized HIV-1 transgenic rats, a model for neuroHIV, and administered repeated methamphetamine.
  • Assessed electrophysiological properties of mPFC astrocytes, focusing on K+ channel activity after acute and repeated methamphetamine exposure.
  • Investigated the role of trace amine-associated receptor 1 (TAAR1) signaling in mediating the observed effects.

Main Results:

  • Both methamphetamine and neuroHIV suppressed astrocytic K+ channel activity.
  • Combined methamphetamine and neuroHIV exposure led to the most significant astrocyte dysfunction.
  • Blocking TAAR1 signaling abolished methamphetamine-induced K+ channel suppression but not neuroHIV-induced suppression.

Conclusions:

  • Methamphetamine and neuroHIV independently and synergistically inhibit astrocyte function.
  • This astrocyte dysfunction may contribute to neuronal dysfunction observed in MUD and neuroHIV.
  • TAAR1 and chemokine receptor signaling pathways are implicated in the effects of methamphetamine and neuroHIV on astrocytic K+ channels.

Related Concept Videos

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
741
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790